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Identity 
Other names: S100PBPR 




There are two different transcript variants of S100PBP. 
Variant 1 is 4317 base pairs and contains 7 exons. 
Variant 2 is 1483 base pairs and also contains 7 exons.  
This is shown in the below alignment. The coding 
sequence for each isoform is indicated in red, with the 
non-coding sequence in grey.  
Unmatched base pairs between the two isoforms are 
highlighted in green and the position of a missing CAG 
codon in isoform B is circled. The end of the isoform B 
sequence is indicated by a bold line. 
Protein 
Description 
S100PBP isoform A codes for a 45 kDa protein and 
isoform B for 37 kDa protein. 
Secondary structure analysis of the S100PBP protein 
sequence was performed using the secondary structure 
consensus prediction tool (NPS@, Lyon, France). 
Based on three different methods: DSC (Discrimination 
of protein Secondary structure Class), MLRC 
(Multivariate Linear Regression Combination) and 
PHD neural network system, S100PBP was shown to 
be largely unstructured and unfolded, as seen below 
("h" represents a helix, "c" a coil and "e" an extended 
strand). 
Expression 
S100PBP is expressed in various normal tissues 
including prostate and lung and in both the endocrine 
and exocrine pancreas.  
S100PBP is also expressed in malignant tissues such as 
liver hepatocellular carcinoma and thyroid carcinoma 
(Lines et al., 2012). 
In pancreas, S100PBP is expressed in decreasing levels 
as cancer develops and progresses, which is an inverse 
pattern of expression of its binding partner, S100P.  
This is shown on picture below (a= acinar cells, d= 
ducts; PanIN= pancreatic intraepithelial neoplasia, a 
precursor lesion to pancreatic cancer, black arrows= 





The exact functions of S100PBP are currently 
unknown, however it has been shown that S100PBP 
can bind to the metastasis related protein S100P 
(Dowen et al., 2005). 
Homology 




No mutations have yet been reported. 
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Implicated in 
Pancreatic ductal adenocarcinoma 
(PDAC) 
Note 
Overexpression of S100PBP in FA6 pancreatic cancer 
cells that show low levels of endogenous  
S100PBP expression and silencing of S100PBP in 
MiaPaCa2 cells (high levels of endogenous S100PBP) 
showed no effect on proliferation or wound healing.  
While cell migration was not affected in majority of 
tested pancreatic cancer cell lines after modulation of 
S100PBP expression, significant changes in invasion 
(increase in MiaPaCa2 and Panc1 cells after S100PBP 
silencing and decrease in RwP1 cells after 
overexpression) were seen. However, the most affected 
cellular function after modulation of S100PBP 
expression was adhesion. Loss of S100PBP causes an 
increase in pancreatic cancer cell adhesion to 
extracellular matrix proteins which was mediated by 
cysteine protease Cathepsin Z (CTSZ) and the integrin 
ανβ5 (Lines et al., 2012). 
Schematic and simplified diagram of the putative 
mechanism behind S100PBP mediated changes in 
pancreatic cell adhesion is shown below: in normal 
cells where S100PBP is highly expressed, low levels of 
CTSZ are present; no or very little ανβ5 is seen on the 
cellular surface. In cancer cells (PDAC), S100PBP 
levels decrease, which results in an increase in CTSZ 
expression; CTSZ is then secreted and can interact with 
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